TW411340B - New crystal modification of CDCH, a process for its preparation and pharmaceutical formulations comprising this modification - Google Patents
New crystal modification of CDCH, a process for its preparation and pharmaceutical formulations comprising this modification Download PDFInfo
- Publication number
- TW411340B TW411340B TW085115048A TW85115048A TW411340B TW 411340 B TW411340 B TW 411340B TW 085115048 A TW085115048 A TW 085115048A TW 85115048 A TW85115048 A TW 85115048A TW 411340 B TW411340 B TW 411340B
- Authority
- TW
- Taiwan
- Prior art keywords
- cdch
- patent application
- item
- scope
- water
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 4
- 239000013078 crystal Substances 0.000 title claims description 34
- 102100034741 Cyclin-dependent kinase 20 Human genes 0.000 title claims description 31
- 101500014379 Lymnaea stagnalis Ovulation hormone Proteins 0.000 title claims description 31
- 230000008569 process Effects 0.000 title abstract description 3
- 230000004048 modification Effects 0.000 title 2
- 238000012986 modification Methods 0.000 title 2
- 150000004682 monohydrates Chemical class 0.000 claims abstract description 26
- 150000001875 compounds Chemical class 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 37
- 238000011049 filling Methods 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 6
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 claims description 5
- 239000012736 aqueous medium Substances 0.000 claims description 4
- 238000002425 crystallisation Methods 0.000 claims description 4
- 230000008025 crystallization Effects 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 230000036571 hydration Effects 0.000 claims 4
- 238000006703 hydration reaction Methods 0.000 claims 4
- 230000009466 transformation Effects 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000009434 installation Methods 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 230000002079 cooperative effect Effects 0.000 description 5
- 238000000113 differential scanning calorimetry Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000001237 Raman spectrum Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- 238000001757 thermogravimetry curve Methods 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 241001454747 Streptomyces aureus Species 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000004455 differential thermal analysis Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000007864 suspending Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19546249A DE19546249A1 (de) | 1995-12-12 | 1995-12-12 | Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW411340B true TW411340B (en) | 2000-11-11 |
Family
ID=7779831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW085115048A TW411340B (en) | 1995-12-12 | 1996-12-06 | New crystal modification of CDCH, a process for its preparation and pharmaceutical formulations comprising this modification |
Country Status (42)
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1895233A (zh) * | 1997-09-25 | 2007-01-17 | 拜尔公司 | 控释活性化合物的药物制剂 |
| DE19751948A1 (de) | 1997-11-24 | 1999-05-27 | Bayer Ag | Verfahren zur Herstellung von 8-Methoxy-Chinoloncarbonsäuren |
| US6509327B1 (en) | 1998-09-30 | 2003-01-21 | Alcon Manufacturing, Ltd. | Compositions and methods for treating otic, ophthalmic and nasal infections |
| US6716830B2 (en) | 1998-09-30 | 2004-04-06 | Alcon, Inc. | Ophthalmic antibiotic compositions containing moxifloxacin |
| US6395746B1 (en) | 1998-09-30 | 2002-05-28 | Alcon Manufacturing, Ltd. | Methods of treating ophthalmic, otic and nasal infections and attendant inflammation |
| DK1128831T3 (da) | 1998-11-10 | 2005-01-17 | Bayer Healthcare Ag | Farmaceutisk moxifloxacinpræparat |
| DE19854357A1 (de) * | 1998-11-25 | 2000-05-31 | Bayer Ag | Semi-Hydrochlorid von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo/4.3.0/ -nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure |
| DE19854356A1 (de) * | 1998-11-25 | 2000-05-31 | Bayer Ag | Kristallmodifikation A von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo-/4.3.0/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure |
| DE19854355A1 (de) * | 1998-11-25 | 2000-05-31 | Bayer Ag | Kristallmodifikation B von 8-Cyan-1-cyclopropyl-7-(1S, 6S-2,8-diazabicyclo-/4.3.O/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure |
| DE19908449A1 (de) * | 1999-02-26 | 2000-08-31 | Bayer Ag | Kristallmodifikation C von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicylo-[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chino/incarbonsäure |
| EP1562942A1 (en) * | 2002-10-31 | 2005-08-17 | Ranbaxy Laboratories, Ltd. | Amorphous moxifloxacin hydrochloride |
| EP2113505A1 (en) | 2003-04-09 | 2009-11-04 | Dr. Reddy's Laboratories, Ltd. | A crystalline form III of anhydrous moxifloxacin hydrochloride and processes for the preparation thereof |
| EP1651630A1 (en) * | 2003-08-05 | 2006-05-03 | Matrix Laboratories Ltd | An improved process for the preparation of moxifloxacin hydrochloride |
| WO2005054240A1 (en) * | 2003-11-20 | 2005-06-16 | Chemi Spa | Polymorphs of 1-cyclopropyl-7-([s,s]-2,8-diazadicyclo[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinoline carboxylic acid hydrochloride and methods for the preparation thereof |
| ITMI20032259A1 (it) | 2003-11-20 | 2005-05-21 | Chemi Spa | Nuovo polimorfo dell'acido 1-ciclopropil-7-(s,s-2,8-diazabciclo-4.3.0-non-8-il)-6-fluoro-1,4-diidro-8-metossi-4-oxo-chinolin carbossilico cloridrato e metodi per la sua preparazione |
| US7491725B2 (en) | 2004-02-06 | 2009-02-17 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
| DE102004015981A1 (de) * | 2004-04-01 | 2005-10-20 | Bayer Healthcare Ag | Neue kirstalline Form von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure |
| DE102004063347A1 (de) * | 2004-12-23 | 2006-07-13 | Stada Arzneimittel Ag | Gebrauchsfertige Gemcitabinlösungen und Gemcitabinlösungskonzentrate |
| WO2007033515A1 (fr) * | 2005-09-21 | 2007-03-29 | Shenzhen Tys R & D Co., Ltd. | Formulation orale contenant de la moxifloxacine et son procédé de préparation |
| GB0612422D0 (en) * | 2006-06-23 | 2006-08-02 | Generics Uk Ltd | Novel hydrate form |
| CN101484411A (zh) | 2006-06-27 | 2009-07-15 | 桑多斯股份公司 | 盐的新制备方法 |
| ES2303768B1 (es) * | 2006-09-08 | 2009-06-05 | Quimica Sintetica, S.A. | Nueva forma cristalina de moxifloxacino clorhidrato. |
| JP2010509305A (ja) * | 2006-11-13 | 2010-03-25 | シプラ・リミテッド | モキシフロキサシン塩酸塩の合成方法 |
| EP1992626A1 (en) * | 2007-05-10 | 2008-11-19 | Sandoz AG | Process for the preparation of moxifloxacin hydrochloride |
| EP2083010A1 (en) * | 2008-01-08 | 2009-07-29 | Chemo Ibérica, S.A. | Polymorphic Forms of Moxifloxacin hydrochloride and processes for preparation thereof |
| EP2154137A1 (en) | 2008-08-04 | 2010-02-17 | Chemo Ibérica, S.A. | Crystalline form of moxifloxacin base |
| EP2349220B1 (en) | 2008-10-09 | 2012-07-25 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Using of organic solvents in wet granulation of moxifloxacin |
| WO2010052726A1 (en) * | 2008-11-06 | 2010-05-14 | Hetero Research Foundation | Novel polymorph of moxifloxacin hydrochloride |
| ES2467105T5 (es) | 2008-12-08 | 2017-12-05 | Ratiopharm Gmbh | Moxifloxacino compactado |
| WO2010131054A1 (en) | 2009-05-15 | 2010-11-18 | Bradford Pharma Limited | Redox drug derivatives |
| WO2011121596A2 (en) * | 2010-04-01 | 2011-10-06 | Neuland Laboratories Ltd. | Crystal modification of moxifloxacin hydrochloride |
| BRPI1106900A2 (pt) | 2011-12-26 | 2013-11-05 | Ems Sa | Composição farmacêutica sólida compreendendo antibótico da familia das quinolonas e processo de sua obtenção |
| FR2992218B1 (fr) | 2012-06-22 | 2015-01-23 | Rivopharm Sa | Composition pharmaceutique de chlorhydrate de moxifloxacine et procede de preparation |
| CN102924449B (zh) * | 2012-10-30 | 2015-08-12 | 重庆福安药业集团庆余堂制药有限公司 | 盐酸莫西沙星h晶型及其制备方法和药物组合物 |
| EP2928892B1 (en) | 2012-12-04 | 2018-03-21 | Mankind Pharma Ltd. | An improved process for the preparation of moxifloxacin hydrochloride |
| RU2561037C2 (ru) * | 2013-02-07 | 2015-08-20 | Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") | Антибактериальная фармацевтическая композиция и способ ее получения |
| AU2014239965A1 (en) | 2013-03-15 | 2015-09-24 | Melinta Subsidiary Corp. | Methods of treating infections in overweight and obese patients using antibiotics |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3601567A1 (de) * | 1986-01-21 | 1987-07-23 | Bayer Ag | 7-(azabicycloalkyl)-chinoloncarbonsaeure- und -naphthyridon-carbonsaeure-derivate |
| DK164287A (da) * | 1986-03-31 | 1987-10-01 | Sankyo Co | Quinolin-3-carboxylsyrederivater og fremgangsmaade til fremstilling deraf og deres anvendelse |
| AU609974B2 (en) * | 1988-05-18 | 1991-05-09 | Warner-Lambert Company | Improved process for the preparation of 5-amino-7- (substituted amino)-quinoline-3-carboxylic acids |
| DE3910663A1 (de) * | 1989-04-03 | 1990-10-04 | Bayer Ag | 5-alkylchinoloncarbonsaeuren |
| RO108347B1 (ro) * | 1989-10-30 | 1994-04-28 | Bellon Labor Sa Roger | DERIVATI DE BENZO-(b)-NAFTIRIDIN-1,8 SI PROCEDEU DE PREPARARE A ACESTORA |
| TW209865B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1992-01-10 | 1993-07-21 | Bayer Ag | |
| CA2128601C (en) * | 1992-01-31 | 2003-07-15 | Hiroyuki Nagano | Quinolone carboxylic acid derivatives in crystalline hydrate form |
| DE4234078A1 (de) * | 1992-10-09 | 1994-04-14 | Bayer Ag | Chinoloncarbonsäuren |
| JP3268098B2 (ja) * | 1992-12-25 | 2002-03-25 | 第一製薬株式会社 | 二環性環状アミン誘導体 |
| ZA946853B (en) * | 1993-09-10 | 1995-04-24 | Daiichi Seiyaku Co | Crystals of antimicrobial compound. |
| EP0676199B1 (en) * | 1994-04-07 | 1998-09-02 | Pfizer Inc. | Use of trovafloxacin or derivatives thereof for the manufacture of a medicament for the treatment of H. pylori infections |
-
1995
- 1995-12-12 DE DE19546249A patent/DE19546249A1/de not_active Withdrawn
-
1996
- 1996-11-22 MA MA24398A patent/MA24342A1/fr unknown
- 1996-11-25 HR HR960558A patent/HRP960558B1/xx not_active IP Right Cessation
- 1996-11-25 RO RO96-02223A patent/RO119782B1/ro unknown
- 1996-11-27 CU CU1996111A patent/CU22774A3/es not_active IP Right Cessation
- 1996-11-29 DE DE59609501T patent/DE59609501D1/de not_active Expired - Lifetime
- 1996-11-29 DK DK96119134T patent/DK0780390T3/da active
- 1996-11-29 PT PT96119134T patent/PT780390E/pt unknown
- 1996-11-29 ES ES96119134T patent/ES2179910T3/es not_active Expired - Lifetime
- 1996-11-29 AT AT96119134T patent/ATE221531T1/de active
- 1996-11-29 SI SI9630468T patent/SI0780390T1/xx unknown
- 1996-11-29 EP EP96119134A patent/EP0780390B1/de not_active Expired - Lifetime
- 1996-12-05 US US08/760,543 patent/US5849752A/en not_active Expired - Lifetime
- 1996-12-05 TR TR96/00970A patent/TR199600970A2/xx unknown
- 1996-12-06 IN IN2723DE1996 patent/IN185805B/en unknown
- 1996-12-06 AU AU74216/96A patent/AU708006B2/en not_active Expired
- 1996-12-06 TW TW085115048A patent/TW411340B/zh not_active IP Right Cessation
- 1996-12-06 YU YU65096A patent/YU49485B/sh unknown
- 1996-12-09 NZ NZ299905A patent/NZ299905A/en not_active IP Right Cessation
- 1996-12-09 AR ARP960105569A patent/AR005009A1/es active IP Right Grant
- 1996-12-09 CA CA002192418A patent/CA2192418C/en not_active Expired - Lifetime
- 1996-12-10 IL IL11979596A patent/IL119795A/en not_active IP Right Cessation
- 1996-12-10 BG BG101043A patent/BG62258B1/bg unknown
- 1996-12-10 ID IDP963684A patent/ID22625A/id unknown
- 1996-12-10 JP JP34450296A patent/JP4104687B2/ja not_active Expired - Lifetime
- 1996-12-10 CO CO96064770A patent/CO4480105A1/es unknown
- 1996-12-10 SG SG1996011612A patent/SG47201A1/en unknown
- 1996-12-10 PL PL96317415A patent/PL184885B1/pl unknown
- 1996-12-11 ZA ZA9610405A patent/ZA9610405B/xx unknown
- 1996-12-11 SK SK1591-96A patent/SK282805B6/sk not_active IP Right Cessation
- 1996-12-11 NO NO19965298A patent/NO306725B1/no not_active IP Right Cessation
- 1996-12-11 BR BR9605968A patent/BR9605968A/pt not_active IP Right Cessation
- 1996-12-11 KR KR1019960064345A patent/KR100525146B1/ko not_active Expired - Lifetime
- 1996-12-11 CZ CZ19963646A patent/CZ288657B6/cs not_active IP Right Cessation
- 1996-12-11 SA SA96170492A patent/SA96170492B1/ar unknown
- 1996-12-11 RU RU96123410/04A patent/RU2162468C2/ru active
- 1996-12-11 EE EE9600201A patent/EE03474B1/xx unknown
- 1996-12-11 MY MYPI96005214A patent/MY117492A/en unknown
- 1996-12-11 UA UA96124628A patent/UA35638C2/uk unknown
- 1996-12-12 SV SV1996000109A patent/SV1996000109A/es active IP Right Grant
- 1996-12-12 HU HU9603428A patent/HU226521B1/hu unknown
- 1996-12-12 CN CN96123220A patent/CN1061348C/zh not_active Expired - Lifetime
-
2002
- 2002-12-05 NL NL300109C patent/NL300109I1/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW411340B (en) | New crystal modification of CDCH, a process for its preparation and pharmaceutical formulations comprising this modification | |
| ES3025633T3 (en) | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer | |
| TWI826446B (zh) | Tlr7/tlr8抑制劑之晶型 | |
| RU2526038C2 (ru) | Тозилатная соль производного 5-пиразолил-2-пиридона, полезная в лечении copd | |
| JP7561240B2 (ja) | ピリジノイルピペリジン５－ｈｔ１ｆアゴニストに関する組成物および方法 | |
| AU2013224897A1 (en) | Novel crystalline form of sitagliptin sulfate | |
| UA44718C2 (uk) | КРИСТАЛІЧНА ФОРМА МЕТАНСУЛЬФОНАТНОЇ СОЛІ 7-([1<font face="Symbol">a</font>,5<font face="Symbol">a</font>,6<font face="Symbol">a</font>]-6-АМІНО-3-АЗАБІЦИКЛО[3.1.0]ГЕКС-3-ІЛ)-6-ФТОР-1-(2,4-ДИФТОРФЕНІЛ)-1,4-ДИГІДРО-4-ОКСО-1,8-НАФТИРИДИН-3-КАРБОНОВОЇ КИСЛОТИ, СПОСІБ ЇЇ ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО МАЄ ПРОТИБАКТЕРІАЛЬНУ АКТИВНІСТЬ, ТА СПОСІБ ЛІКУВАННЯ БАКТЕРІАЛЬНОЇ ІНФЕКЦІЇ | |
| CN117769540A (zh) | 4-[5-[(3S)-3-氨基吡咯烷-l-羰基]-2-[2-氟-4-(2-羟基-2-乙基丙基)苯基]苯基]-2-氟-苯甲腈的盐的固体形式 | |
| TWI285204B (en) | Polymorphs of a crystalline azabicyclo[2,2.2]octan-3-amine citrate and their pharmaceutical compositions | |
| US10717729B2 (en) | Thiamine-organic acid salt | |
| JP2024530315A (ja) | Ｂｃｌ－２阻害剤の固体形態、それらの調製方法及び使用方法 | |
| WO2022162107A1 (en) | Crystalline form of risdiplam | |
| JP2021533111A (ja) | Ｌｔａ４ｈ阻害剤の結晶形態 | |
| EP3517529B1 (en) | Salt of quinazoline derivative, preparation method therefor and application thereof | |
| Pipkin | Towards using mesoporous silica as a drug delivery system for chlorpromazine ibuprofenate ionic liquid | |
| MXPA96006325A (en) | New variante cristalina del cdch, procedure for its production and pharmaceutical preparations that contains it | |
| JP2023524622A (ja) | ６－クロロ－７－（４－（４－クロロベンジル）ピペラジン－１－イル）－２－（１，３－ジメチル－１Ｈ－ピラゾール－４－イル）－３Ｈ－イミダゾ［４，５－ｂ］ピリジンの塩及び多形体 | |
| KR20210141936A (ko) | 셀리넥서의 공결정 형태 | |
| WO2020187674A1 (en) | Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate | |
| HK1002006A (en) | Crystalline modification of cdch, process for its preparation and pharmaceutical compositions containing it | |
| HK1002006B (en) | Crystalline modification of cdch, process for its preparation and pharmaceutical compositions containing it |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GD4A | Issue of patent certificate for granted invention patent | ||
| MK4A | Expiration of patent term of an invention patent |